ERIN FEENEY: Open Payments
NPI 1053902999 · CAIRO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,468 in 82 payments from 20 companies in 2025. Trend: 2023 $2,588 · 2024 $2,688 · 2025 $1,468
Food & beverage: $1,468
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $221 |
| GlaxoSmithKline, LLC. | 11 | $210 |
| Lilly USA, LLC | 6 | $196 |
| PFIZER INC. | 14 | $148 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $122 |
| Novo Nordisk Inc | 5 | $114 |
| Janssen Pharmaceuticals, Inc | 3 | $84 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $61 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
Products named: TRELEGY ELLIPTA, ZEPBOUND, NURTEC ODT, Kerendia, Wegovy, VRAYLAR, SPRAVATO, XIFAXAN.
Industry payments across NY — which companies pay providers there.
